Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity.
Ciliary Neurotrophic Factor (CNTF) was first characterized as a trophic factor for motor neurons in the ciliary ganglion and spinal cord, leading to its evaluation in humans suffering from motor neuron disease. In these trials, CNTF caused unexpected and substantial weight loss, raising concerns that it might produce cachectic-like effects. Countering this possibility was the suggestion that CNTF was working via a leptin-like mechanism to cause weight loss, based on the findings that CNTF acts via receptors that are not only related to leptin receptors, but also similarly distributed within hypothalamic nuclei involved in feeding. However, although CNTF mimics the ability of leptin to cause fat loss in mice that are obese because of genetic deficiency of leptin (ob/ob mice), CNTF is also effective in diet-induced obesity models that are more representative of human obesity, and which are resistant to leptin. This discordance again raised the possibility that CNTF might be acting via nonleptin pathways, perhaps more analogous to those activated by cachectic cytokines. Arguing strongly against this possibility, we now show that CNTF can activate hypothalamic leptin-like pathways in diet-induced obesity models unresponsive to leptin, that CNTF improves prediabetic parameters in these models, and that CNTF acts very differently than the prototypical cachectic cytokine, IL-1. Further analyses of hypothalamic signaling reveals that CNTF can suppress food intake without triggering hunger signals or associated stress responses that are otherwise associated with food deprivation; thus, unlike forced dieting, cessation of CNTF treatment does not result in binge overeating and immediate rebound weight gain.
Lambert
P D
PD
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. philip.lambert@regpha.com
Anderson
K D
KD
Sleeman
M W
MW
Wong
V
V
Tan
J
J
Hijarunguru
A
A
Corcoran
T L
TL
Murray
J D
JD
Thabet
K E
KE
Yancopoulos
G D
GD
Wiegand
S J
SJ
D000273:Adipose Tissue; D000818:Animals; D002100:Cachexia; D020934:Ciliary Neurotrophic Factor / Q000494:pharmacology*; D003345:Corticosterone / Q000097:blood; D004268:DNA-Binding Proteins / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D007375:Interleukin-1 / Q000502:physiology; D020738:Leptin / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000378:metabolism* / Q000503:physiopathology; D050796:STAT3 Transcription Factor; D015534:Trans-Activators / Q000378:metabolism; D015430:Weight Gain; D015431:Weight Loss
D020934:Ciliary Neurotrophic Factor; D004268:DNA-Binding Proteins; D007375:Interleukin-1; D020738:Leptin; D050796:STAT3 Transcription Factor; C494087:Stat3 protein, mouse; D015534:Trans-Activators; D003345:Corticosterone